Pay in 4 interest-free payments of $5.68 Learn more
Ships within 48 hours · Estimated delivery Sep 5 - Sep 10
Clinical Safety Screens Performed MTC personal AND family history in the comorbidity multi-select MEN-2 personal AND family history separately Substance / opioid screen with three-month opiate window + free-text dose, frequency, dates Suicidality and recent suicide attempt as exclusionary opt-out Active cancer treatment and cancer-free-for-five-years exclusionary End-stage kidney and liver disease opt-out Severe GI screen (gastroparesis, blockage, IBD) Pancreatitis history in the multi-select Self-reported blood pressure range and resting heart rate Past 2-month GLP-1 use (semaglutide / tirzepatide / none) No validated PHQ-2 or PHQ-9 depression instrument suicidality is captured as a binary exclusionary opt-out and severe depression is a checkbox on the comorbidity multi-select, but the validated brief screening scale is not used
On government insurance, you might qualify for Extra Help or a Medicare Savings Program
Like any medication, everyone responds a little differently
Oral doses are capsules, not syringe units
Individuals who used semaglutide or tirzepatide previously and experienced minimal gastrointestinal distress have bodies already adapted to the receptor activation patterns
